BD Pharmingen- PE Mouse Anti-Human MIP-1- -CCL3_BD Pharmingen
参考图片
Flow cytometric analysis of MIP-1α (CCL3) expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS (10 ng/ml) in the presence of GolgiStop™ (Cat. No. 554724; aka monensin 2 µM). The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 (Cat. No. 555397), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Mouse Anti-Human MIP-1α (CCL3) (Cat. No. 554730) following Pharmingen's staining protocol (left panel). The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1α (CCL3) was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1α (0.5 µg; middle panel), and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody (5.0 µg, right panel) prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody (right panel) blocking specificity controls.
本文来自投稿,不代表本人立场,如若转载,请注明出处:http://www.iamyjet.com/kangti/9726.html